Chad WhiteheadAudit Partner
Ernst & Young LLP
Chad is an audit partner at Ernst & Young in the San Diego office. Chad has over 14 years of experience serving public (ranging from small to large multi-national) and venture backed clients in the life sciences, medical device, technology and media and entertainment industries. Chad recently relocated to San Diego from the EY London office after finishing a three-year assignment where he served as the United Kingdom Biotech/Medtech leader the past two years.
Throughout Chad’s career he has assisted clients in convertible debt offerings, IPOs, follow-on offerings, mergers and acquisitions, cross-border transactions and numerous ‘34 Act filings. Some of the public clients Chad has served include: Gilead, Bio-rad, Smith & Nephew, Santarus, Halozyme, Neurocrine, Vical, CV Therapeutics, Renovis, Sun Microsystems, Time Warner and AOL.
During his assignment in London, Chad was very active in presenting EY Thought Leadership to various biotech and medtech organizations including BIA, OBN, LBN, and Medtech UK. In 2006, Chad helped establish the EY Global Biotechnology Center in Boston where he created several pieces of Thought Leadership. Prior to his assignment in London, Chad spent five years in the Bay Area serving mid-market companies and also some of the firm’s largest biotechnology and technology clients. Chad has also worked in Ernst & Young’s Salt Lake City and Buenos Aires offices.
Chad received a B.A. in Accounting and MBA both from the University of Utah and is on the Board of the University of Utah School of Accounting. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.
I am on the JA board because... I have a passion for education. As a parent of five children I want to do everything I can to ensure their successful future.
I volunteer for JA because... Because education is the answer and provides children with multiple options to effectively contribute to society and make a difference.
My company donates to JA because... We help to build tomorrow's workforce.